A phase 2 trial found that adding bevacizumab to alectinib significantly delayed disease progression, protected against brain ...

DelveInsight’s Meningioma Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Meningioma treatment. The leading Meningioma Companies such as NX ...

As the oncology community prepares for the 2025 American Society of Clinical Oncology Annual Meeting, anticipation is running ...

CRISPR Therapeutics announced an agreement with Sirius Therapeutics to develop and commercialize small interfering RNA (siRNA ...

During a live event, Samuel M. Rubinstein, MD, discussed the efficacy and safety outcomes from the KarMMa-3 trial.

CTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with In combination with pembrolizumab, ADG126 showed a 29% confirmed overall response rate (ORR) in microsatelli ...

This study identifies 53BP1 as an interaction partner of GMCL1 (a likely CUL3 substrate receptor). The study seeks to link this finding to regulation of the mitotic surveillance pathway and paclitaxel ...

Of the 157 000 children living with HIV in South Africa, around one in three are not getting the medicines they need to stay ...

The Trump administration’s mass federal layoffs and cancellation of research grants are having effects in communities far ...

Vienna, Austria played host to a momentous gathering, welcoming over 15,000 attendees from across five continents for the ...

The spectre of COVID-19, a pandemic that reshaped the world, is creeping back into focus across Asia, and Goa cannot afford to lower its guard. Reports from Sin ...

Monoclonal antibodies against SARS-CoV-2 were considered a promising approach for the prevention and therapy of coronavirus ...